{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:45:55Z","timestamp":1782625555142,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,27]]},"DOI":"10.7759\/cureus.111633","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:43:31Z","timestamp":1782625411000},"source":"Crossref","is-referenced-by-count":0,"title":["ETV6-NTRK3 Fusion-Positive Late-Recurrent Parotid Carcinoma With Contralateral Axillary Metastasis and Early Response to Entrectinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Cristina Alexandra","family":"Manea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Grigorean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin Gabriel","family":"Smarandache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru Cristinel","family":"Badiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1 A","year":"2010","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Sima R, et al.. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010, 34:599-608. 10.1097\/PAS.0b013e3181d9efcc","journal-title":"Am J Surg Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1667","article-title":"Disease distribution and temporal trends of salivary gland cancer: a global population-based study","volume":"14","author":"Huang J","year":"2024","unstructured":"Huang J, Fung YC, Pang WS, et al.. Disease distribution and temporal trends of salivary gland cancer: a global population-based study. Clin Transl Med. 2024, 14:e1667. 10.1002\/ctm2.1667","journal-title":"Clin Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041293","article-title":"Primary and secondary tumors of the parotid gland: clinical features and prognosis","volume":"15","author":"Pecorari G","year":"2023","unstructured":"Pecorari G, Pizzo C, Briguglio M, Cravero E, Riva G. Primary and secondary tumors of the parotid gland: clinical features and prognosis. Cancers. 2023, 15:1293. 10.3390\/cancers15041293","journal-title":"Cancers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/lary.24254","article-title":"Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy","volume":"124","author":"Sethi R","year":"2014","unstructured":"Sethi R, Kozin E, Remenschneider A, et al.. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014, 124:188-95. 10.1002\/lary.24254","journal-title":"Laryngoscope"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco E","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018, 15:731-47. 10.1038\/s41571-018-0113-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2 C","year":"2019","unstructured":"Marchi\u00f2 C, Scaltriti M, Ladanyi M, et al.. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019, 30:1417-27. 10.1093\/annonc\/mdz204","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations","volume":"26","author":"Rosen EY","year":"2020","unstructured":"Rosen EY, Goldman DA, Hechtman JF, et al.. TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res. 2020, 26:1624-32. 10.1158\/1078-0432.CCR-19-3165","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00815-4","article-title":"TRK fusion cancer: patient characteristics and survival analysis in the real-world setting","volume":"16","author":"Bazhenova L","year":"2021","unstructured":"Bazhenova L, Lokker A, Snider J, et al.. TRK fusion cancer: patient characteristics and survival analysis in the real-world setting. Target Oncol. 2021, 16:389-99. 10.1007\/s11523-021-00815-4","journal-title":"Target Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018, 378:731-9. 10.1056\/NEJMoa1714448","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al.. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:271-82. 10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri GD","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, et al.. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022, 28:1302-12. 10.1158\/1078-0432.CCR-21-3597","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen C","year":"2022","unstructured":"van Herpen C, Vander Poorten V, Skalova A, et al.. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2022, 7:100602. 10.1016\/j.esmoop.2022.100602","journal-title":"ESMO Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0427-1","article-title":"Characterization of novel genetic alterations in salivary gland secretory carcinoma","volume":"33","author":"Na K","year":"2020","unstructured":"Na K, Hernandez-Prera JC, Lim JY, Woo HY, Yoon SO. Characterization of novel genetic alterations in salivary gland secretory carcinoma. Mod Pathol. 2020, 33:541-50. 10.1038\/s41379-019-0427-1","journal-title":"Mod Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-024-01673-y","article-title":"ETV6 molecular heterogeneity in salivary secretory carcinoma: a case series report and literature review","volume":"18","author":"Mahomed F","year":"2024","unstructured":"Mahomed F, de Bruin J, Ngwenya S, Masango Z, Hodkinson K. ETV6 molecular heterogeneity in salivary secretory carcinoma: a case series report and literature review. Head Neck Pathol. 2024, 18:66. 10.1007\/s12105-024-01673-y","journal-title":"Head Neck Pathol"},{"key":"ref16","article-title":"Types of cervical lymph node dissection in the maxillofacial region: a review article","volume":"11","author":"Yankov YG","year":"2025","unstructured":"Yankov YG, Stoev LL, Yotsova RV, Gerova-Vatsova T, Ali M. Types of cervical lymph node dissection in the maxillofacial region: a review article. Scr Sci Med Dent. 2025, 11:39-44.","journal-title":"Scr Sci Med Dent"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1247435","article-title":"Case report: a case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer","volume":"13","author":"Moriyama E","year":"2023","unstructured":"Moriyama E, Nagasu S, Tanaka T, et al.. Case report: a case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer. Front Oncol. 2023, 13:1247435. 10.3389\/fonc.2023.1247435","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01155-6","article-title":"Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report","volume":"15","author":"Suzuki K","year":"2022","unstructured":"Suzuki K, Harada H, Takeda M, et al.. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report. BMC Med Genomics. 2022, 15:6. 10.1186\/s12920-022-01155-6","journal-title":"BMC Med Genomics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32792","article-title":"Distant metastasis of salivary gland cancer: Incidence, management, and outcomes","volume":"126","author":"Mimica X","year":"2020","unstructured":"Mimica X, McGill M, Hay A, et al.. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer. 2020, 126:2153-62. 10.1002\/cncr.32792","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ohn.167","article-title":"Patterns of lymph node metastasis in parotid cancer and implications for extent of neck dissection","volume":"168","author":"Voora RS","year":"2023","unstructured":"Voora RS, Panuganti B, Califano J, Coffey C, Guo T. Patterns of lymph node metastasis in parotid cancer and implications for extent of neck dissection. Otolaryngol Head Neck Surg. 2023, 168:1067-78. 10.1002\/ohn.167","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4076\/1752-1947-3-7230","article-title":"Axillary nodal metastasis at primary presentation of an oropharyngeal primary carcinoma: a case report and review of the literature","volume":"3","author":"McKenzie BJ","year":"2009","unstructured":"McKenzie BJ, Loock JW. Axillary nodal metastasis at primary presentation of an oropharyngeal primary carcinoma: a case report and review of the literature. J Med Case Rep. 2009, 3:7230. 10.4076\/1752-1947-3-7230","journal-title":"J Med Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/014556131008900807","article-title":"A case of head and neck cancer metastasizing to the axillary lymph nodes","volume":"89","author":"Wormald R","year":"2010","unstructured":"Wormald R, Sheahan P, Timon C. A case of head and neck cancer metastasizing to the axillary lymph nodes. Ear Nose Throat J. 2010, 89:E24-6. 10.1177\/014556131008900807","journal-title":"Ear Nose Throat J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2017.02.434","article-title":"Axillary nodal metastasis in patient with head and neck carcinoma: a case report","volume":"46","author":"Khairi J","year":"2017","unstructured":"Khairi J, Oo AL. Axillary nodal metastasis in patient with head and neck carcinoma: a case report. Int J Oral Maxillofac Surg. 2017, 46:124. 10.1016\/j.ijom.2017.02.434","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.024","article-title":"Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma","volume":"31","author":"Lukovic J","year":"2020","unstructured":"Lukovic J, Alfaraj FA, Mierzwa ML, et al.. Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma. Ann Oncol. 2020, 31:295-301. 10.1016\/j.annonc.2019.10.024","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/gs-2024-575","article-title":"Intra-parotid lymph node metastasis in primary parotid gland cancer: a narrative review of its significance, anatomic distribution, and therapeutic implications","volume":"14","author":"Jang JY","year":"2025","unstructured":"Jang JY, Jeong HS. Intra-parotid lymph node metastasis in primary parotid gland cancer: a narrative review of its significance, anatomic distribution, and therapeutic implications. Gland Surg. 2025, 14:761-70. 10.21037\/gs-2024-575","journal-title":"Gland Surg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29060314","article-title":"TRK inhibition with entrectinib in metastatic salivary secretory carcinoma (SC): a case report","volume":"29","author":"Ernst MS","year":"2022","unstructured":"Ernst MS, Lysack JT, Hyrcza MD, Chandarana SP, Hao D. TRK inhibition with entrectinib in metastatic salivary secretory carcinoma (SC): a case report. Curr Oncol. 2022, 29:3933-9. 10.3390\/curroncol29060314","journal-title":"Curr Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28196","article-title":"Conversion surgery after administration of a TRK inhibitor for unresectable parotid gland secretory carcinoma","volume":"47","author":"Nagano A","year":"2025","unstructured":"Nagano A, Matoba T, Kawakita D, et al.. Conversion surgery after administration of a TRK inhibitor for unresectable parotid gland secretory carcinoma. Head Neck. 2025, 47:E116-21. 10.1002\/hed.28196","journal-title":"Head Neck"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504231-etv6-ntrk3-fusion-positive-late-recurrent-parotid-carcinoma-with-contralateral-axillary-metastasis-and-early-response-to-entrectinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:43:32Z","timestamp":1782625412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504231-etv6-ntrk3-fusion-positive-late-recurrent-parotid-carcinoma-with-contralateral-axillary-metastasis-and-early-response-to-entrectinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.111633","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}